Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06545331 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT06545331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06545331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Recruiting
Start date
August 6, 2024
Completion date
October 20, 2027
Enrollment
396 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell cancer, head and neck squamous cell cancer, hormone-receptor-positive breast cancer, locally advanced or metastatic solid tumors, nsclc (non-small cell lung cancer), triple negative breast cancer (tnbc)